307 related articles for article (PubMed ID: 22171621)
41. Recombinant factor VIIa in the management of surgery and acute bleeding episodes in children with haemophilia and high-responding inhibitors.
Smith OP
Pathophysiol Haemost Thromb; 2002; 32 Suppl 1():22-5. PubMed ID: 12214142
[TBL] [Abstract][Full Text] [Related]
42. Pharmacokinetics and pharmacodynamics of recombinant factor VIIa.
Lindley CM; Sawyer WT; Macik BG; Lusher J; Harrison JF; Baird-Cox K; Birch K; Glazer S; Roberts HR
Clin Pharmacol Ther; 1994 Jun; 55(6):638-48. PubMed ID: 8004880
[TBL] [Abstract][Full Text] [Related]
43. PERSEPT 1: a phase 3 trial of activated eptacog beta for on-demand treatment of haemophilia inhibitor-related bleeding.
Wang M; Lawrence JB; Quon DV; Ducore J; Simpson ML; Boggio LN; Mitchell IS; Yuan G; Alexander WA; Schved JF
Haemophilia; 2017 Nov; 23(6):832-843. PubMed ID: 28776894
[TBL] [Abstract][Full Text] [Related]
44. Use of the UKHCDO Database for a postmarketing surveillance study of different doses of recombinant factor VIIa in haemophilia.
Hay CRM; Sharpe T; Dolan G;
Haemophilia; 2017 May; 23(3):376-382. PubMed ID: 28026073
[TBL] [Abstract][Full Text] [Related]
45. Sequential combined bypassing therapy is safe and effective in the treatment of unresponsive bleeding in adults and children with haemophilia and inhibitors.
Gringeri A; Fischer K; Karafoulidou A; Klamroth R; López-Fernández MF; Mancuso E;
Haemophilia; 2011 Jul; 17(4):630-5. PubMed ID: 21323801
[TBL] [Abstract][Full Text] [Related]
46. Approaches towards successful home treatment in patients with inhibitors.
Ingerslev J; Thykjaer H; Scheibel E
Eur J Haematol Suppl; 1998; 63():11-4. PubMed ID: 9882926
[TBL] [Abstract][Full Text] [Related]
47. Safety and pharmacokinetics of subcutaneously administered recombinant activated factor VII (rFVIIa).
Tiede A; Friedrich U; Stenmo C; Allen G; Giangrande P; Goudemand J; Hay C; Holmström M; Klamroth R; Lethagen S; McKenzie S; Miesbach W; Negrier C; Yuste VJ; Berntorp E
J Thromb Haemost; 2011 Jun; 9(6):1191-9. PubMed ID: 21489128
[TBL] [Abstract][Full Text] [Related]
48. Single-dose recombinant activated factor VII for the treatment of joint bleeds in hemophilia patients with inhibitors.
Shapiro AD
Clin Adv Hematol Oncol; 2008 Aug; 6(8):579-86. PubMed ID: 18820600
[TBL] [Abstract][Full Text] [Related]
49. First 20 years with recombinant FVIIa (NovoSeven).
Hedner U; Lee CA
Haemophilia; 2011 Jan; 17(1):e172-82. PubMed ID: 20609014
[TBL] [Abstract][Full Text] [Related]
50. A comparison of traditional vs. Canadian tailored prophylaxis dosing of prophylactic factor infusions in children with haemophilia A and B in a single hemophilia treatment center.
Dodd C; Watts RG
Haemophilia; 2012 Jul; 18(4):561-7. PubMed ID: 22221939
[TBL] [Abstract][Full Text] [Related]
51. NovoSeven (recombinant factor VIIa) in centeral nervous systems bleeds.
Rice KM; Savidge GF
Haemostasis; 1996; 26 Suppl 1():131-4. PubMed ID: 8904187
[TBL] [Abstract][Full Text] [Related]
52. Recombinant activated factor VII in the treatment of bleeds and for the prevention of surgery-related bleeding in congenital haemophilia with inhibitors.
Santagostino E; Escobar M; Ozelo M; Solimeno L; Arkhammar P; Lee HY; Rosu G; Giangrande P
Blood Rev; 2015 Jun; 29 Suppl 1():S9-18. PubMed ID: 26073369
[TBL] [Abstract][Full Text] [Related]
53. Replacement therapy for bleeding episodes in factor VII deficiency. A prospective evaluation.
Mariani G; Napolitano M; Dolce A; Pérez Garrido R; Batorova A; Karimi M; Platokouki H; Auerswald G; Bertrand AM; Di Minno G; Schved JF; Bjerre J; Ingerslev J; Sørensen B; Ruiz-Saez A; ;
Thromb Haemost; 2013 Feb; 109(2):238-47. PubMed ID: 23238632
[TBL] [Abstract][Full Text] [Related]
54. Safety and effectiveness of room temperature stable recombinant factor VIIa in patients with haemophilia A or B and inhibitors: Results of a multinational, prospective, observational study.
Kavakli K; Demartis F; Karimi M; Eshghi P; Neme D; Chambost H; Sommer L; Zak M; Benson G
Haemophilia; 2017 Jul; 23(4):575-582. PubMed ID: 28440004
[TBL] [Abstract][Full Text] [Related]
55. Efficacy of recombinant activated factor VII vs. activated prothrombin complex concentrate for patients suffering from haemophilia complicated with inhibitors: a Bayesian meta-regression.
Treur MJ; McCracken F; Heeg B; Joshi AV; Botteman MF; De Charro F; Van Hout B
Haemophilia; 2009 Mar; 15(2):420-36. PubMed ID: 19335751
[TBL] [Abstract][Full Text] [Related]
56. Lessons from a systematic literature review of the effectiveness of recombinant factor VIIa in acquired haemophilia.
Tiede A; Worster A
Ann Hematol; 2018 Oct; 97(10):1889-1901. PubMed ID: 29804265
[TBL] [Abstract][Full Text] [Related]
57. Current use of by-passing agents in Europe in the management of acute bleeds in patients with haemophilia and inhibitors.
Astermark J; Rocino A; Von Depka M; Van Den Berg HM; Gringeri A; Mantovani LG; Morado M; Garrido RP; Schiavoni M; Villar A; Windyga J;
Haemophilia; 2007 Jan; 13(1):38-45. PubMed ID: 17212723
[TBL] [Abstract][Full Text] [Related]
58. Cost-Effectiveness of rFVIIa versus pd-aPCC in the Management of Mild to Moderate Bleeds in Pediatric Patients with Hemophilia A with Inhibitors in Mexico.
Rodríguez-Zepeda MDC; González L; Bravo A; Pompa T; Silva S; Paredes R; García J; Ramos M; Wilkinson L; Lamotte M
Value Health Reg Issues; 2018 Dec; 17():164-173. PubMed ID: 30317158
[TBL] [Abstract][Full Text] [Related]
59. Early treatment with recombinant factor VIIa results in greater efficacy with less product.
Lusher JM
Eur J Haematol Suppl; 1998; 63():7-10. PubMed ID: 9882925
[TBL] [Abstract][Full Text] [Related]
60. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]